Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Sign Up to like & getrecommendations! Published in 2017 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2017.09.028
Abstract: BACKGROUND Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be depleted by alemtuzumab, thereby potentially contributing… read more here.
Keywords: alemtuzumab treatment; treatment; year; alemtuzumab ... See more keywords
B cell depletion therapy resulting in sustained remission of severe autoimmune complications following Alemtuzumab treatment of Multiple Sclerosis.
Sign Up to like & getrecommendations! Published in 2019 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2019.07.016
Abstract: Secondary autoimmune disorders (AID) are a recognised complication of alemtuzumab treatment for multiple sclerosis. We have previously reported two female multiple sclerosis patients treated with alemtuzumab who developed rare but severe secondary AID; acquired haemophilia… read more here.
Keywords: treatment multiple; alemtuzumab treatment; treatment; multiple sclerosis ... See more keywords